Total Payments
$1.0M
2024 Payments
$101,533
Companies
27
Transactions
1,175
Payment Breakdown by Category
Other$464,183 (46.2%)
Consulting$250,969 (25.0%)
Travel$182,494 (18.1%)
Education$72,477 (7.2%)
Research$18,877 (1.9%)
Food & Beverage$16,798 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $403,433 | 211 | 40.1% |
| Consulting Fee | $250,969 | 142 | 25.0% |
| Travel and Lodging | $182,494 | 390 | 18.1% |
| Education | $72,477 | 104 | 7.2% |
| Honoraria | $60,750 | 28 | 6.0% |
| Unspecified | $18,877 | 18 | 1.9% |
| Food and Beverage | $16,798 | 282 | 1.7% |
Payments by Type
General
$986,922
1,157 transactions
Research
$18,877
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BioMarin Pharmaceutical Inc. | $431,560 | 603 | $0 (2024) |
| Shire North American Group Inc | $133,234 | 179 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $111,554 | 65 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $61,690 | 88 | $0 (2024) |
| GENZYME CORPORATION | $59,732 | 62 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $40,995 | 13 | $0 (2019) |
| Ultragenyx Pharmaceutical Inc. | $30,676 | 12 | $0 (2024) |
| Horizon Therapeutics plc | $29,395 | 18 | $0 (2023) |
| PTC Therapeutics, Inc. | $28,792 | 29 | $0 (2024) |
| Horizon Pharma plc | $18,645 | 18 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $101,533 | 81 | BioMarin Pharmaceutical Inc. ($26,244) |
| 2023 | $101,003 | 151 | BioMarin Pharmaceutical Inc. ($54,779) |
| 2022 | $107,190 | 94 | BioMarin Pharmaceutical Inc. ($64,783) |
| 2021 | $63,983 | 47 | Takeda Pharmaceuticals U.S.A., Inc. ($38,596) |
| 2020 | $84,919 | 69 | BioMarin Pharmaceutical Inc. ($40,524) |
| 2019 | $198,826 | 272 | BioMarin Pharmaceutical Inc. ($88,649) |
| 2018 | $154,346 | 211 | BioMarin Pharmaceutical Inc. ($97,352) |
| 2017 | $193,999 | 250 | Shire North American Group Inc ($74,924) |
All Payment Transactions
1,175 individual payment records from CMS Open Payments — Page 1 of 47
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/31/2024 | BioMarin Pharmaceutical Inc. | — | Consulting Fee | Cash or cash equivalent | $2,967.18 | General |
| 12/18/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ELAPRASE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,490.56 | General |
| Category: GENETIC DISEASE | ||||||
| 12/12/2024 | Chiesi USA, Inc. | LAMZEDE (Drug) | Honoraria | Cash or cash equivalent | $300.00 | General |
| Category: ERT FOR ALPHA-MANNOSIDOSIS | ||||||
| 12/12/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $225.00 | General |
| 12/12/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $225.00 | General |
| 12/10/2024 | Alexion Pharmaceuticals, Inc. | KANUMA (Biological) | Food and Beverage | In-kind items and services | $62.02 | General |
| Category: Rare Disease | ||||||
| 12/05/2024 | Chiesi USA, Inc. | LAMZEDE (Drug) | Honoraria | Cash or cash equivalent | $3,395.00 | General |
| Category: ERT FOR ALPHA-MANNOSIDOSIS | ||||||
| 12/05/2024 | BioMarin Pharmaceutical Inc. | Palynziq (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: PKU | ||||||
| 11/14/2024 | PTC Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| 11/14/2024 | PTC Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $667.11 | General |
| 11/14/2024 | PTC Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $79.43 | General |
| 11/14/2024 | PTC Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $41.44 | General |
| 11/14/2024 | PTC Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $25.77 | General |
| 11/13/2024 | PTC Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $79.43 | General |
| 11/12/2024 | PTC Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $14,312.43 | General |
| 11/12/2024 | PTC Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $52.99 | General |
| 11/07/2024 | BioMarin Pharmaceutical Inc. | Palynziq (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: PKU | ||||||
| 11/07/2024 | BioMarin Pharmaceutical Inc. | VIMIZIM (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $500.00 | General |
| Category: MPS IVA | ||||||
| 10/25/2024 | Amgen Inc. | RAVICTI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,555.00 | General |
| Category: Metabolic Disorders/Rare Disease | ||||||
| 10/22/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ELAPRASE (Biological) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: GENETIC DISEASE | ||||||
| 10/15/2024 | PTC Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 10/15/2024 | PTC Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $882.25 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MEASuRE | Aegerion Pharmaceuticals, Inc. | $5,945 | 3 |
| Lysosomal Acid Lipase LAL Deficiency Registry ALX-LALD-501 | Alexion Pharmaceuticals, Inc. | $4,713 | 4 |
| A Phase 3, Open-Label, Multi-Center Study to Assess the Safety and Efficacy of BMN 165 in Japanese Subjects 18 Years of Age and Older With Phenylketonuria | BioMarin Pharmaceutical Inc. | $3,771 | 1 |
| A Global, Phase 1/2, Open-label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA 3927 in Participants with Propionic Acidemia | ModernaTX, Inc. | $1,950 | 3 |
| A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID) | Takeda Pharmaceuticals U.S.A., Inc. | $1,748 | 5 |
| A Global, Phase 1/2, Open-label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA 3927 in Participants with Propionic Acidemia | Moderna TX, Inc. | $450.00 | 1 |
| Morquio A Registry Study MARS) | BioMarin Pharmaceutical Inc. | $300.00 | 1 |
About Dr. Barbara Burton, MD
Dr. Barbara Burton, MD is a Clinical Genetics (M.D.) healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699743088.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Barbara Burton, MD has received a total of $1.0M in payments from pharmaceutical and medical device companies, with $101,533 received in 2024. These payments were reported across 1,175 transactions from 27 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($403,433).
Ad
Practice Information
- Specialty Clinical Genetics (M.D.)
- Location Chicago, IL
- Active Since 03/10/2006
- Last Updated 07/08/2007
- Taxonomy Code 207SG0201X
- Entity Type Individual
- NPI Number 1699743088
Products in Payments
- Palynziq (Drug) $183,585
- ELAPRASE (Biological) $133,280
- Kuvan (Drug) $81,700
- Vimizim (Biological) $52,381
- Kanuma (Drug) $43,834
- RAVICTI (Drug) $43,738
- ALDURAZYME (Drug) $39,512
- NO PRODUCT DISCUSSED (Drug) $30,264
- BMN 165 (Biological) $12,939
- RAVICTI (Biological) $10,515
- DISEASE STATE (Drug) $10,434
- MYOZYME (Drug) $8,337
- DOJOLVI (Drug) $6,400
- MYALEPT (Drug) $5,945
- BMN 165 (Drug) $4,875
- LAMZEDE (Drug) $3,901
- Naglazyme (Biological) $3,819
- VIMIZIM (Biological) $3,200
- VPRIV (Biological) $2,131
- ALDURAZYME (Biological) $1,560
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Clinical Genetics (M.D.) Doctors in Chicago
Dr. Joshua Baker, D.o, D.O
Clinical Genetics (M.D.) — Payments: $160,734
Clinical Genetics (M.D.) $160,734
Mr. Jeffrey Dungan, M.d, M.D
Clinical Genetics (M.D.) — Payments: $3,875
Clinical Genetics (M.D.) $3,875
Dr. Susan Echiverri, M.d, M.D
Clinical Genetics (M.D.) — Payments: $1,759
Clinical Genetics (M.D.) $1,759
Miguel Barajas, Md, MD
Clinical Genetics (M.D.) — Payments: $778.43
Clinical Genetics (M.D.) $778.43
Andrew Wagner, Md, MD
Clinical Genetics (M.D.) — Payments: $156.32
Clinical Genetics (M.D.) $156.32
Dr. Edward Jones, Md, MD
Clinical Genetics (M.D.) — Payments: $124.98
Clinical Genetics (M.D.) $124.98